Cargando…

No evidence for cardiotoxicity of miltefosine()

Detalles Bibliográficos
Autor principal:	Dorlo, Thomas P.C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Dermatologia 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263634/ https://www.ncbi.nlm.nih.gov/pubmed/35654652 http://dx.doi.org/10.1016/j.abd.2022.03.002

Ejemplares similares

No evidence for cardiotoxicity of miltefosine – Reply()
por: Barroso, Daniel Holanda, et al.
Publicado: (2022)

Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation
por: Palić, Semra, et al.
Publicado: (2019)

Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis
por: Castro, María del Mar, et al.
Publicado: (2017)

Failure of Miltefosine Treatment for Visceral Leishmaniasis in Children and Men in South-East Asia
por: Ostyn, Bart, et al.
Publicado: (2014)

Dynamics of Parasite Clearance in Cutaneous Leishmaniasis Patients Treated with Miltefosine
por: Dorlo, Thomas P. C., et al.
Publicado: (2011)

Comparison of cardiotoxicity between N-methyl-glucamine and miltefosine in the treatment of American cutaneous leishmaniasis()()
por: Barroso, Daniel Holanda, et al.
Publicado: (2021)

1662. Pushing the Dose: Miltefosine Treatment for a Supersized American with Cutaneous Leishmaniasis
por: Aronson, Naomi E, et al.
Publicado: (2019)

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial
por: Wasunna, Monique, et al.
Publicado: (2016)

Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa
por: Palić, Semra, et al.
Publicado: (2020)

Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis
por: Verrest, Luka, et al.
Publicado: (2023)

Focus on anticancer therapy-induced cardiotoxicity from the perspective of oncologists
por: Liu, Binliang, et al.
Publicado: (2022)

Safety and Efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial
por: Omollo, Raymond, et al.
Publicado: (2011)

New advances in medical imaging technology for the evaluation of anthracycline-induced cardiotoxicity
por: Su, Nan, et al.
Publicado: (2022)

Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection
por: Kip, A. E., et al.
Publicado: (2016)

Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management
por: Sundar, Shyam, et al.
Publicado: (2007)

Oral miltefosine for refractory Acanthamoeba keratitis
por: Hirabayashi, Kristin E., et al.
Publicado: (2019)

Case report: challenges in monitoring and treatment of anthracycline induced cardiotoxicity in young adults with osteosarcoma
por: Heemelaar, Julius C., et al.
Publicado: (2022)

Immune checkpoint inhibitors-associated cardiotoxicity in immunotherapy trials on gastrointestinal cancer patients
por: Li, Yiqun, et al.
Publicado: (2022)

Emergence, development, and future of cardio-oncology in China: cardiohypersensitivity, cardiotoxicity and the Kounis syndrome
por: Kounis, Nicholas G., et al.
Publicado: (2019)

Increased Leishmania infantum resistance to miltefosine and amphotericin B after treatment of a dog with miltefosine and allopurinol
por: Gonçalves, Gustavo, et al.
Publicado: (2021)

Repurposing of Miltefosine as an Adjuvant for Influenza Vaccine
por: Lu, Lu, et al.
Publicado: (2020)

Proton beam therapy causing pericarditis – a rare case of radiation induced cardiotoxicity
por: Gupta, Rahul, et al.
Publicado: (2022)

Miltefosine enhances infectivity of a miltefosine-resistant Leishmania infantum strain by attenuating its innate immune recognition
por: Bulté, Dimitri, et al.
Publicado: (2021)

Screening and management of dyslipidemia in oncologic patients undergoing cardiotoxic therapies: results from an Italian survey
por: Camilli, Massimiliano, et al.
Publicado: (2023)

Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial
por: Mbui, Jane, et al.
Publicado: (2019)

Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study
por: Dorlo, Thomas P C, et al.
Publicado: (2017)

Leishmania Resistance to Miltefosine Associated with Genetic Marker
por: Cojean, Sandrine, et al.
Publicado: (2012)

SUCCESSFUL TREATMENT OF MULTIFOCAL CUTANEOUS LEISHMANIASIS WITH MILTEFOSINE
por: Madke, Bhushan, et al.
Publicado: (2011)

Complex cutaneous infection by Leishmania mexicana treated with miltefosine
por: Sadowsky, Rachel L., et al.
Publicado: (2022)

MDR1 causes resistance to the antitumour drug miltefosine
por: Rybczynska, M, et al.
Publicado: (2001)

Successful Treatment of Disseminated Acanthamoeba sp. Infection with Miltefosine
por: Aichelburg, Alexander C., et al.
Publicado: (2008)

Breast cancer and the pill - response to the letter from R.D.T. Farmer
por: Kay, C.R., et al.
Publicado: (1989)

Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial
por: Musa, Ahmed M, et al.
Publicado: (2022)

Fitness and Phenotypic Characterization of Miltefosine-Resistant Leishmania major
por: Turner, Kimbra G., et al.
Publicado: (2015)

Mitochondrial Proteomics of Antimony and Miltefosine Resistant Leishmania infantum
por: Vincent, Isabel M., et al.
Publicado: (2015)

Miltefosine Rescue Treatment for Visceral Leishmaniasis Relapse Patient
por: Bastola, Anup, et al.
Publicado: (2019)

Lingual Leishmaniasis Presenting to Maxillofacial Surgery in UK with Successful Treatment with Miltefosine
por: Kassam, K., et al.
Publicado: (2013)

Miltefosine Suppresses Hepatic Steatosis by Activating AMPK Signal Pathway
por: Fang, Ru, et al.
Publicado: (2016)

New insights with miltefosine unresponsiveness in Brazilian Leishmania infantum isolates
por: Bhattacharya, Arijit, et al.
Publicado: (2018)

Glutamine supplementation improves the efficacy of miltefosine treatment for visceral leishmaniasis
por: Ferreira, Carolina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vu0fr6c1hfq7fg58ugd6bm7qjs